龙津药业(002750) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥7,187,051.64, a decrease of 73.79% compared to the same period last year[2]. - The net profit attributable to shareholders was -¥5,106,035.06, representing a 53.00% increase in losses year-over-year[2]. - The net profit after deducting non-recurring gains and losses was -¥5,044,748.27, a 60.90% increase in losses compared to the previous year[2]. - The company's basic earnings per share were -¥0.0127, a 53.00% increase in losses compared to the same period last year[2]. - The company incurred a net loss of ¥11,696,710.84, compared to a loss of ¥31,262,417.58 in the previous period, showing an improvement in financial performance[15]. - The net profit for the third quarter was -12,556,935.33 CNY, an improvement from -32,395,816.44 CNY in the same period last year, indicating a reduction in losses by approximately 61.2%[16]. - The total comprehensive income for the period was -12,556,935.33 CNY, compared to -32,395,816.44 CNY in the previous year, reflecting a significant decrease in overall losses[16]. Assets and Liabilities - Total assets at the end of the reporting period were ¥597,371,058.17, down 5.42% from the end of the previous year[2]. - The company's total assets decreased to ¥597,371,058.17 from ¥631,634,251.67, a decline of 5.4%[14]. - The total liabilities decreased to ¥68,754,690.64 from ¥90,507,766.87, a reduction of 24.1%[14]. - The company's total liabilities decreased by 5.42% compared to the previous year, reflecting a reduction in financial leverage[2]. - The company’s equity attributable to shareholders decreased to ¥502,556,915.86 from ¥511,886,948.80, a decline of 1.3%[14]. Cash Flow - The company's cash flow from operating activities was -¥32,732,160.62, a decrease of 31.65% compared to the previous year[2]. - Net cash flow from operating activities improved by 31.65%, amounting to RMB -32,732,160.62, compared to RMB -47,892,397.89 last year[6]. - Cash inflow from operating activities was 60,148,170.55 CNY, down from 87,982,914.62 CNY year-over-year, representing a decline of about 31.7%[18]. - Cash outflow from operating activities totaled 92,880,331.17 CNY, compared to 135,875,312.51 CNY in the previous year, showing a decrease of approximately 31.6%[18]. - The net cash flow from operating activities was -32,732,160.62 CNY, an improvement from -47,892,397.89 CNY in the same quarter last year[18]. - The net cash flow from investing activities increased by 262.61% to RMB 86,166,339.97 from RMB -52,988,058.32 year-on-year[6]. - The net cash flow from investing activities was 86,166,339.97 CNY, a turnaround from -52,988,058.32 CNY in the previous year, indicating a positive shift in investment returns[18]. - The company reported a cash inflow from financing activities of 12,398,021.04 CNY, compared to 3,087,800.00 CNY in the previous year, indicating a substantial increase in financing[19]. Expenses - The company reported a significant decrease in sales expenses by 39.13% to ¥29,634,245.45 due to lower marketing costs[5]. - Research and development expenses decreased by 55.92% to ¥5,625,567.39, reflecting a reduction in project spending[5]. - Research and development expenses decreased by 53.29% to RMB 11,695,329.19 from RMB 25,038,457.55 year-on-year[6]. - Research and development expenses were reported at ¥5,625,567.39, down from ¥12,762,122.74, a decrease of 55.8%[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,887, with the largest shareholder holding 39.40%[7]. - The company’s major shareholder, Kunming Qunxing Investment Co., Ltd., holds 39.40% of the shares, amounting to 157,782,293 shares[7]. Market Conditions - The company experienced a 67% drop in the bidding price for its main product, leading to a significant decline in sales volume and revenue[5]. - The company’s core product prices have decreased by 67% due to centralized procurement policies, leading to a decline in sales volume across provinces[9]. - The company has been warned of potential delisting due to negative net profit and revenue below ¥100 million in the 2023 annual report[11].